breast cancer
Conditions
Interventions
For every PTX infusion, each patient wore the 2 smaller SG on one hand (compression therapy side
CT side), and the 2 SG that fit on the other hand (control side) for 90 minutes: the 30 minutes before the administration of PTX, the 30 minutes of PTX infusion itself, and the 30 minutes after the en
Sponsors
Aichi Cancer Center
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Who started chemotherapy of wPTX 80mg/m2(plusminus Trastuzumab or Bevacizumab or Pertuzumab plusminus Trastuzumab) 2.ECOG performance status 0 or 1 3.Adequate bone marrow,heart,liver and renal function 4.Informed consent is obtainable from the subject herself in documented form using the Consent Form
Exclusion criteria
Exclusion criteria: 1.Already have peripheral neuropathy >grade 1 by CTCAE v4.0 2.Previous chemotherapy treatment of PTX or nab-PTX 3.The patients whose peripheral intravenous injection is possible only in the area where the gloves are worn 4.History of Raynaud syndrome, hepatitis or other active infectious disease and uncontrolled diabetes 5.Any condition for contraindication of chemotherapy 6.Multiple active cancers (homochromous multiple cancers, or heterochromous multiple cancers with a cancer-free period of less than 5 years prior to randomization) Carcinoma in situ deemed to be cured by local treatment (lesions that are intraepithelial carcinoma or mucosal cancer) is not included as an active multiple cancer 7.Active brain metastasis which require immediate medical procedure or radiation therapy 8.Pleural effusion, ascites or pericardial effusion which require immediate medical procedure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference in the frequency of occurrence of CIPN (motor/sensory) between the CT side hand and the control side hand was determined by the physician in charge using the Common Terminology Criteria for Adverse Events scale version 4.0 (CTCAE v4.0). Grade 2 or more were considered to be CIPN. | — |
Countries
Japan
Contacts
Public ContactHaruru Kotani
Aichi Cancer Center Department of Breast Oncology
Outcome results
None listed